98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369583 | PMC |
http://dx.doi.org/10.1016/j.ensci.2020.100254 | DOI Listing |
Comput Methods Programs Biomed
August 2025
School of Computer Science and Technology, Southwest University of Science and Technology, Mianyang 621010, China. Electronic address:
Background: Carotid web (CaW) is a rare fibromuscular dysplasia lesion at the carotid bifurcation linked to thromboembolic events in young patients. CaW-induced hemodynamic disturbances contribute to thrombosis, but the impact of CaW morphology on long-term thrombotic risk remains unclear.
Method: This study developed three-dimensional numerical models based on patient-specific carotid artery anatomy with CaW angles of 30°, 60°, and 90° (models A, B, and C).
JACC Clin Electrophysiol
August 2025
TriHealth Heart & Vascular Institute, Bethesda North Hospital, Cincinnati, Ohio, USA. Electronic address:
Biomaterials
August 2025
Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Capital Medical University, Beijing, 100069, China; Neuro Cardio Vas
The systemic administration of low-molecular-weight heparin (LMWH) as the standard initial treatment for venous thromboembolism is intended to prevent thrombus growth during the acute phase and prevent thrombus recurrence during the chronic phase. However, precisely controlling the specificity and localization of LMWH presents significant challenges, which has necessitated research into targeted delivery methods. Furthermore, due to different thrombosis mechanisms, tailored pharmacologic interventions are needed, particularly for arterial and venous thrombosis.
View Article and Find Full Text PDFAnn Med Surg (Lond)
September 2025
Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe.
Venous thromboembolism (VTE) remains a significant cause of morbidity and mortality in breast cancer patients, particularly in those with advanced disease or undergoing systemic therapies. While breast cancer is not traditionally classified among the most thrombogenic malignancies, accumulating evidence suggests that tumor biology, treatment modalities, and systemic inflammation can collectively heighten thrombotic risk. This has led to a growing interest in the concept of , wherein the coagulation cascade and inflammatory responses are intricately linked, creating a prothrombotic and tumor-supportive environment.
View Article and Find Full Text PDFDrug Des Devel Ther
September 2025
Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang, 050051, People's Republic of China.
Background: Apixaban and rivaroxaban are oral direct factor Xa inhibitors, primarily eliminated through CYP3A4-mediated metabolism and direct intestinal excretion. Previous studies suggest that palbociclib, a CDK4/6 inhibitor, may increase the systemic exposure of these anticoagulants; however, the specific pharmacokinetic mechanisms remain unclear. This study aims to evaluate the effects of palbociclib on the pharmacokinetics of apixaban and rivaroxaban using a rat model to optimize combined drug regimens.
View Article and Find Full Text PDF